Nanocrystal Core Lipoprotein Biomimetics for Imaging of Lipoproteins and Associated Diseases

Current Cardiovascular Imaging Reports

Volumn 6, Issue 1, 2013, Pages 45-54

  Fay, Francois ^a   Sanchez Gaytan, Brenda L ^a   Cormode, David P ^b   Skajaa, Torjus ^c   Fisher, Edward A ^d   Fayad, Zahi A ^a   Mulder, Willem J M ^a,e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c AARHUS UNIVERSITY   (Denmark)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Cancer; Gold nanoparticles; Iron oxide nanoparticles; Lipoproteins; Quantum dots

Indexed keywords

EID: 84872507279     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-012-9181-1     Document Type: Review

References (56)

1. Singaraja RR, Stahmer B, Brundert M, et al. Hepatic ATP-binding cassette transporter A1 is a key molecule in high-density lipoprotein cholesteryl ester metabolism in mice. Arterioscler Thromb Vasc Biol. 2006; 26: 1821-7.
2. Brundert M, Ewert A, Heeren J, et al. Scavenger receptor class B type I mediates the selective uptake of high-density lipoprotein-associated cholesteryl ester by the liver in mice. Arterioscler Thromb Vasc Biol. 2005; 25: 143-8.
3. Cormode DP, Chandrasekar R, Delshad A, et al. Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug Chem. 2009; 20: 937-43.
4. Zhang Y, Zanotti I, Reilly MP, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003; 108: 661-3.
5. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004; 126: 16316-7.
6. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res. 2004; 45: 1594-607.
7. • Skajaa T, Zhao Y, van den Heuvel DJ, et al. Quantum dot and Cy5. 5 labeled nanoparticles to investigate lipoprotein biointeractions via Förster resonance energy transfer. Nano Lett. 2010; 10: 5131-8. This paper describes the development of FRET QD-HDL to study interactions between lipoproteins and lipid exchange dynamics.
8. Shaish A, Keren G, Chouraqui P, Levkovitz H, Harats D. Imaging of aortic atherosclerotic lesions by (125)I-LDL, (125)I-oxidized-LDL, (125)I-HDL and (125)I-BSA. Pathobiology. 2001; 69: 225-9.
9. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955; 34: 1345-53.
10. Segrest JP, Jones MK, De Loof H, et al. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res. 1992; 33: 141-66.
11. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992; 258: 468-71.
12. Mahley RW, Rall Jr SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000; 1: 507-37.
13. Baitsch D, Bock HH, Engel T, et al. Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol. 2011; 31: 1160-8.
14. Goldstein JL, Brown MS, Anderson RG, Russell DW, Schneider WJ. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol. 1985; 1: 1-39.
15. Lehr HA, Becker M, Marklund SL, et al. Superoxide-dependent stimulation of leukocyte adhesion by oxidatively modified LDL in vivo. Arterioscler Thromb. 1992; 12: 824-9.
16. Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin Chim Acta. 2012; 413: 3-14.
17. Firestone RA. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem. 1994; 5: 105-13.
18. Maletinska L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res. 2000; 60: 2300-3.
19. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006; 116: 3090-100.
20. Oram JF. HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol. 2003; 23: 720-7.
21. Wang MD, Franklin V, Marcel YL. In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Arterioscler Thromb Vasc Biol. 2007; 27: 1837-42.
22. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res. 2004; 95: 764-72.
23. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003; 278: 9142-9.
24. Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005; 111: 1543-50.
25. Nofer JR, Remaley AT. Tangier disease: still more questions than answers. Cell Mol Life Sci. 2005; 62: 2150-60.
26. Merchant B. Gold, the noble metal and the paradoxes of its toxicology. Biologicals. 1998; 26: 49-59.
27. Galper MW, Saung MT, Fuster V, et al. Effect of computed tomography scanning parameters on gold nanoparticle and iodine contrast. Invest Radiol. 2012; 47: 475-81.
28. Yguerabide J, Yguerabide EE. Light-scattering submicroscopic particles as highly fluorescent analogs and their use as tracer labels in clinical and biological applications. Anal Biochem. 1998; 262: 157-76.
29. You J, Zhang R, Xiong C, et al. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res. 2012; 72: 4777-86.
30. Yilmaz A, Rosch S, Klingel K, et al. Magnetic resonance imaging (MRI) of inflamed myocardium using iron oxide nanoparticles in patients with acute myocardial infarction-preliminary results. Int J Cardiol. 2011. doi: 10. 1016/j. ijcard. 2011. 06. 004.
31. Kimura K, Tanigawa N, Matsuki M, et al. High-resolution MR lymphography using ultrasmall superparamagnetic iron oxide (USPIO) in the evaluation of axillary lymph nodes in patients with early stage breast cancer: preliminary results. Breast Cancer. 2010; 17: 241-6.
32. Tang TY, Howarth SP, Miller SR, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol. 2009; 53: 2039-50.
33. Chandrasekharan P, Maity D, Yong CX, Chuang KH, Ding J, Feng SS. Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials. 2011; 32: 5663-72.
34. Trivedi RA, Mallawarachi C, U-King-Im JM, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol. 2006; 26: 1601-6.
35. Bruners P, Braunschweig T, Hodenius M, et al. Thermoablation of malignant kidney tumors using magnetic nanoparticles: an in vivo feasibility study in a rabbit model. Cardiovasc Intervent Radiol. 2010; 33: 127-34.
36. Voura EB, Jaiswal JK, Mattoussi H, Simon SM. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med. 2004; 10: 993-8.
37. Liu J, Lau SK, Varma VA, Kairdolf BA, Nie S. Multiplexed detection and characterization of rare tumor cells in Hodgkin's lymphoma with multicolor quantum dots. Anal Chem. 2010; 82: 6237-43.
38. Liu H, Liu Y, Liu S, Pang DW, Xiao G. Clathrin-mediated endocytosis in living host cells visualized through quantum dot labeling of infectious hematopoietic necrosis virus. J Virol. 2011; 85: 6252-62.
39. Prasuhn DE, Feltz A, Blanco-Canosa JB, et al. Quantum dot peptide biosensors for monitoring caspase 3 proteolysis and calcium ions. ACS Nano. 2010; 4: 5487-97.
40. • Thaxton CS, Daniel WL, Giljohann DA, Thomas AD, Mirkin CA. Templated spherical high density lipoprotein nanoparticles. J Am Chem Soc. 2009; 131: 1384-5. This paper describes the synthesis of Au-HDL which are able to bind cholesterol.
41. Luthi AJ, Zhang H, Kim D, et al. Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS Nano. 2012; 6: 276-85.
42. • McMahon KM, Mutharasan RK, Tripathy S, et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett. 2011; 11: 1208-14. This paper describes the development of an Au-HDL platform to deliver nucleic acids.
43. • Cormode DP, Skajaa T, van Schooneveld MM, et al. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett. 2008; 8: 3715-23. This paper describes the development of nanocrystal core HDL (Au-HDL, FeO-HDL, QD-HDL) as multimodality imaging platforms.
44. • Bruns OT, Ittrich H, Peldschus K, et al. Real-time magnetic resonance imaging and quantification of lipoprotein metabolism in vivo using nanocrystals. Nat Nanotechnol. 2009; 4: 193-201. This paper describes the development of QD/FeO core triglyceride-rich lipoproteins to study their metabolism.
45. Cormode DP, Roessl E, Thran A, et al. Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology. 2010; 256: 774-82.
46. Skajaa T, Cormode DP, Jarzyna PA, et al. The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials. 2011; 32: 206-13.
47. Bartelt A, Bruns OT, Reimer R, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011; 17: 200-5.
48. • Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008; 451: 953-7. This review describes the different techniques and strategies to image arteriosclerotic vascular disease.
49. Lindsay AC, Choudhury RP. Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov. 2008; 7: 517-29.
50. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008; 452: 580-9.
51. Zheng G, Li H, Zhang M, Lund-Katz S, Chance B, Glickson JD. Low-density lipoprotein reconstituted by pyropheophorbide cholesteryl oleate as target-specific photosensitizer. Bioconjug Chem. 2002; 13: 392-6.
52. Wu SP, Lee I, Ghoroghchian PP, et al. Near-infrared optical imaging of B16 melanoma cells via low-density lipoprotein-mediated uptake and delivery of high emission dipole strength tris[(porphinato)zinc(II)] fluorophores. Bioconjug Chem. 2005; 16: 542-50.
53. Corbin IR, Li H, Chen J, et al. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia. 2006; 8: 488-98.
54. Yamakoshi Y, Qiao H, Lowell AN, et al. LDL-based nanoparticles for contrast enhanced MRI of atheroplaques in mouse models. Chem Commun (Camb). 2011; 47: 8835-7.
55. Chen W, Vucic E, Leupold E, et al. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging. 2008; 3: 233-42.
56. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 2006; 6: 2220-4.